• PDF: Delivered by email usually within 12 to 24 UK business hours.

Respiratory Syncytial Virus (RSV) Infections - Pipeline Review
H1 2013

Respiratory Syncytial Virus (RSV) Infections - Pipeline Review H1 2013

Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2013

Summary

Global Markets Direct's, 'Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Respiratory Syncytial Virus (RSV) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Respiratory Syncytial Virus (RSV) Infections. Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Respiratory Syncytial Virus (RSV) Infections.
  • A review of the Respiratory Syncytial Virus (RSV) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Respiratory Syncytial Virus (RSV) Infections pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Respiratory Syncytial Virus (RSV) Infections.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus (RSV) Infections pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • Introduction
    • Global Markets Direct Report Coverage
    • Respiratory Syncytial Virus (RSV) Infections Overview
  • Therapeutics Development
    • An Overview of Pipeline Products for Respiratory Syncytial Virus (RSV) Infections
    • Respiratory Syncytial Virus (RSV) Infections Therapeutics under Development by Companies
    • Respiratory Syncytial Virus (RSV) Infections Therapeutics under Investigation by Universities/Institutes
    • Late Stage Products
    • Comparative Analysis
    • Mid Clinical Stage Products
    • Comparative Analysis
    • Early Clinical Stage Products
    • Comparative Analysis
    • Discovery and Pre-Clinical Stage Products
    • Comparative Analysis
    • Respiratory Syncytial Virus (RSV) Infections Therapeutics - Products under Development by Companies
    • Respiratory Syncytial Virus (RSV) Infections Therapeutics - Products under Investigation by Universities/Institutes
  • Companies Involved in Respiratory Syncytial Virus (RSV) Infections Therapeutics Development
    • Johnson & Johnson
    • Bavarian Nordic A/S
    • MedImmune LLC
    • Gilead Sciences, Inc.
    • GenVec, Inc.
    • Ablynx
    • Symphogen A/S
    • Celltrion, Inc.
    • Novavax, Inc.
    • Crucell N.V.
    • DBV Technologies
    • Mymetics Corporation
    • Pevion Biotech Ltd
    • Alnylam Pharmaceuticals, Inc
    • Functional Genetics, Inc.
    • LigoCyte Pharmaceuticals, Inc.
    • Mucosis B.V.
    • Okairos
    • AlphaVax, Inc.
    • Kineta, Inc.
    • Kenta Biotech Ltd.
    • Romark Laboratories, L.C.
    • REPLICor Inc.
    • Wittycell S.A.S.
    • NanoBio Corporation
    • ImmunoVaccine Technologies Inc.
    • iBio, Inc.
    • Sirnaomics, Inc.
    • Alios BioPharma, Inc.
    • Merus B.V.
    • AIMM Therapeutics B.V.
    • MicroDose Therapeutx, Inc.
    • AmVac AG
    • SelectX Pharmaceuticals, Inc.
    • Spider Biotech S.r.l.
    • Clarassance, Inc.
    • Respiratory Syncytial Virus (RSV) Infections
  • Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ALN-RSV-01 - Drug Profile
    • MEDI-559 - Drug Profile
    • MEDI-557 - Drug Profile
    • Sym-003 - Drug Profile
    • MVA-BN RSV - Drug Profile
    • Vaccine For RSV - Drug Profile
    • KBRV-201 - Drug Profile
    • MDT-637 - Drug Profile
    • REP-9AC - Drug Profile
    • RSV Vaccine - Drug Profile
    • RI-001 - Drug Profile
    • ALX-0171 - Drug Profile
    • PEV-4 - Drug Profile
    • Respiratory Syncytial Virus (RSV) Vaccine - Drug Profile
    • RSV VLP Vaccine - Drug Profile
    • RV-568 - Drug Profile
    • RSV Vaccine - Drug Profile
    • palivizumab biosimilar - Drug Profile
    • RSV Vaccine - Drug Profile
    • SLP-1001 - Drug Profile
    • SLP-0904 - Drug Profile
    • Mucosal Respiratory Syncytial Virus Vaccine - Drug Profile
    • New Thiazolides - Drug Profile
    • Respiratory Syncytial Virus Vaccine Programme - Drug Profile
    • STP-902 - Drug Profile
    • Drug For Infectious Disease - Drug Profile
    • RSV Vaccine - Drug Profile
    • SynGEM - Drug Profile
    • RSV Vaccine - Drug Profile
    • RIG-I Pathway Program - Drug Profile
    • rOAS-1 - Drug Profile
    • FGI-110 - Drug Profile
    • CG-100 - Drug Profile
    • AMV-603 - Drug Profile
    • AMV-611 - Drug Profile
    • ALS-8112 - Drug Profile
    • ALS-8176 - Drug Profile
    • RSV Non-Nucleosides - Drug Profile
    • AMV-601 - Drug Profile
    • AMV-602 - Drug Profile
    • Monoclonal Antibody For RSV - Drug Profile
    • SB-105 - Drug Profile
    • Respiratory Syncytial Virus Vaccine - Drug Profile
    • RSV Program - Drug Profile
    • Anti-Viral Program - Drug Profile
    • WTCa Adjuvant - Drug Profile
    • WTCb Adjuvant - Drug Profile
    • WTCn Adjuvant - Drug Profile
    • GS-5806 - Drug Profile
    • RSV-NanoViaSkin - Drug Profile
    • BTAC-286 - Drug Profile
    • RI-002 - Drug Profile
    • RSV VLP Vaccine - Drug Profile
    • Antibody Against RSV - Drug Profile
    • Respiratory Syncytial Virus (RSV) Infections Therapeutics - Drug Profile Updates
    • Respiratory Syncytial Virus (RSV) Infections Therapeutics - Discontinued Products
    • Respiratory Syncytial Virus (RSV) Infections Therapeutics - Dormant Products
    • Respiratory Syncytial Virus (RSV) Infections - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • R&D Progress
  • Disclaimer
  • List of Tables
    • Number of Products Under Development for Respiratory Syncytial Virus (RSV) Infections, H1 2013
    • Products under Development for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis, H1 2013
    • Number of Products under Development by Companies, H1 2013
    • Number of Products under Development by Companies, H1 2013 (Contd..1)
    • Number of Products under Development by Companies, H1 2013 (Contd..2)
    • Number of Products under Investigation by Universities/Institutes, H1 2013
    • Comparative Analysis by Late Stage Development, H1 2013
    • Comparative Analysis by Mid Clinical Stage Development, H1 2013
    • Comparative Analysis by Early Clinical Stage Development, H1 2013
    • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013
    • Products under Development by Companies, H1 2013
    • Products under Development by Companies, H1 2013 (Contd..1)
    • Products under Development by Companies, H1 2013 (Contd..2)
    • Products under Development by Companies, H1 2013 (Contd..3)
    • Products under Investigation by Universities/Institutes, H1 2013
    • Johnson & Johnson, H1 2013
    • Bavarian Nordic A/S, H1 2013
    • MedImmune LLC, H1 2013
    • Gilead Sciences, Inc., H1 2013
    • GenVec, Inc., H1 2013
    • Ablynx, H1 2013
    • Symphogen A/S, H1 2013
    • Celltrion, Inc., H1 2013
    • Novavax, Inc., H1 2013
    • Crucell N.V., H1 2013
    • DBV Technologies, H1 2013
    • Mymetics Corporation, H1 2013
    • Pevion Biotech Ltd, H1 2013
    • Alnylam Pharmaceuticals, Inc, H1 2013
    • Functional Genetics, Inc., H1 2013
    • LigoCyte Pharmaceuticals, Inc., H1 2013
    • Mucosis B.V., H1 2013
    • Okairos, H1 2013
    • AlphaVax, Inc., H1 2013
    • Kineta, Inc., H1 2013
    • Kenta Biotech Ltd., H1 2013
    • Romark Laboratories, L.C., H1 2013
    • REPLICor Inc., H1 2013
    • Wittycell S.A.S., H1 2013
    • NanoBio Corporation, H1 2013
    • ImmunoVaccine Technologies Inc., H1 2013
    • iBio, Inc., H1 2013
    • Sirnaomics, Inc., H1 2013
    • Alios BioPharma, Inc., H1 2013
    • Merus B.V., H1 2013
    • AIMM Therapeutics B.V., H1 2013
    • MicroDose Therapeutx, Inc., H1 2013
    • AmVac AG, H1 2013
    • SelectX Pharmaceuticals, Inc., H1 2013
    • Spider Biotech S.r.l., H1 2013
    • Clarassance, Inc., H1 2013
    • Assessment by Monotherapy Products, H1 2013
    • Assessment by Stage and Route of Administration, H1 2013
    • Assessment by Stage and Molecule Type, H1 2013
    • Respiratory Syncytial Virus (RSV) Infections Therapeutics - Drug Profile Updates
    • Respiratory Syncytial Virus (RSV) Infections Therapeutics - Discontinued Products
    • Respiratory Syncytial Virus (RSV) Infections Therapeutics - Dormant Products
  • List of Figures
    • Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H1 2013
    • Products under Development for Respiratory Syncytial Virus (RSV) Infections - Comparative Analysis, H1 2013
    • Products under Development by Companies, H1 2013
    • Products under Investigation by Universities/Institutes, H1 2013
    • Late Stage Products, H1 2013
    • Mid Clinical Stage Products, H1 2013
    • Early Clinical Stage Products, H1 2013
    • Discovery and Pre-Clinical Stage Products, H1 2013
    • Assessment by Monotherapy Products, H1 2013
    • Assessment by Route of Administration, H1 2013
    • Assessment by Stage and Route of Administration, H1 2013
    • Assessment by Molecule Type, H1 2013
    • Assessment by Stage and Molecule Type, H1 2013
+44 20 8816 8548

Ask a question about Respiratory Syncytial Virus (RSV) Infections - Pipeline Review

Enter the characters you see in the picture below
Captcha